Group B Streptococcus: Developing a correlate of protection for a vaccine against neonatal infections

Current Opinion in Infectious Diseases

Volumn 29, Issue 3, 2016, Pages 262-267

  Dangor, Ziyaad ^a,b   Lala, Sanjay G ^b   Kwatra, Gaurav ^a   Madhi, Shabir A ^a,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

correlates; Group B Streptococcus; immunity; Streptococcus agalactiae; vaccine

Indexed keywords

GROUP B STREPTOCOCCUS VACCINE; MATERNAL ANTIBODY; MEMBRANE PROTEIN; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; BACTERIUM ANTIBODY;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL COLONIZATION; BREAST MILK; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; MEDLINE; NEWBORN INFECTION; NONHUMAN; PREGNANT WOMAN; REVIEW; STREPTOCOCCUS AGALACTIAE; VACCINATION; BLOOD; CHEMISTRY; FEMALE; IMMUNOLOGY; INFANT, NEWBORN, DISEASES; NEWBORN; PREGNANCY; STREPTOCOCCAL INFECTIONS;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; POLYSACCHARIDES, BACTERIAL; PREGNANCY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84959207094     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000266     Document Type: Review

References (58)

1. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 2013; 31 (Suppl 4):D20-D26.
2. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011; 30:937-941.
3. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016-2025.
4. Okike IO, Johnson AP, Henderson KL, et al. Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United Kingdom and republic of ireland: prospective, enhanced, national population-based surveillance. Clin Infect Dis 2014; 59:e150-e157.
5. Dangor Z, Lala SG, Cutland CL, et al. Burden of invasive group B streptococcus disease and early neurological sequelae in South African infants. PloS One 2015; 10:e0123014.
6. Rappuoli R, Black S. Introduction: addressing the challenge of group B streptococcal disease. Vaccine 2013; 31 (Suppl 4):D1-D2.
7. Dangor Z, Kwatra G, Izu A, et al. Review on the association of group B streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccine 2015; 14:135-149.
8. Baker CJ, Rench MA, McInnes P.Immunization ofpregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21:3468-3472.
9. Edwards MS, Lane HJ, Hillier SL, et al. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine 2012; 30:4123-4126.
10. Heyderman RS, Madhi SA, French N, et al. A phase II open-label, multi-center study of a group B streptococcus vaccine in HIV-infected and HIV-uninfected pregnant women in Africa. Lancet Infect Dis 2015; In Press.
11. Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early-and late-onset invasive disease in young-infants. Vaccine 2013; 31 (Suppl 4):D52-D57.
12. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-1065.
13. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27 (Suppl 2):B112-B116.
14. The European Agency for the Evaluation of Medicinal Products. Note for the guidance on harmonisation of requirements for Influenza vaccines. 1997. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003945.pdf.
15. World Health Organization Immunization Vaccines, Biologicals W. Measuring impact of Streptococcus pneumoniae and Haemophilus influenzae type b conjugate vaccination. Geneva: Expanded Programme on Immunization (EPI) of the Department of Immunization, Vaccines and Biologicals; 2012. p. 36.
16. Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 2014; 209:781-788.
17. Dangor Z, Kwatra G, Izu A, et al. Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants. Vaccine 2015; 33:6793-6799.
18. Le Doare K, Allen L, Kampmann B, et al. Antigroup B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection. Vaccine 2015; 33:621-627.
19. Dangor Z, Kwatra G, Izu A, et al. HIV-1 is associated with lower group B streptococcus capsular and surface protein IgG antibody levels and reduced transplacental antibody transfer in pregnant women. J Infect Dis 2015; 212:453-462.
20. Kwatra G, Adrian PV, Shiri T, et al. Natural acquired humoral immunity against serotype-specific Group B Streptococcus recto-vaginal colonization acquisition in pregnant women. Clin Microbiol Infect 2015; 21:568.e13-e21.
21. Mu R, Kim BJ, Paco C, et al. Identification of a group B streptococcal fibronectin binding protein, SfbA, that contributes to invasion of brain endothelium and development of meningitis. Infect Immun 2014; 82:2276-2286.
22. Buscetta M, Papasergi S, Firon A, et al. FbsC, a novel fibrinogen-binding protein, promotes streptococcus agalactiae-host cell interactions. J Biol Chem 2014; 289:21003-21015.
23. Altindis E, Cozzi R, Di Palo B, et al. Protectome analysis: a new selective bioinformatics tool for bacterial vaccine candidate discovery. Mol Cell Pro-teomics 2015; 14:418-429.
24. Dangor Z, Kwatra G, Izu A, et al. Association between maternal group B streptococcus surface protein antibody concentrations and invasive disease in their infants. Expert Rev Vaccines 2015; 14:1651-1660.
25. Nilo A, Morelli L, Passalacqua I, et al. Anti-group B streptococcus glycan-con-jugate vaccines using pilus protein GBS80 as carrier and antigen: comparing lysine and tyrosine-directed conjugation. ACS Chem Biol 2015; 10:1737-1746.
26. Nilo A, Passalacqua I, Fabbrini M, et al. Exploring the effect of conjugation site and chemistry on the immunogenicity of an anti-group B streptococcus glycoconjugate vaccine based on GBS67 pilus protein and type V polysac-charide. Bioconjug Chem 2015; 26:1839-1849.
27. Padler-Karavani V, Hurtado-Ziola N, Chang YC, et al. Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates. FASEB J 2014; 28:1280-1293.
28. Chang YC, Olson J, Beasley FC, et al. Group B streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo. PLoS Pathog 2014; 10:e1003846.
29. Chang YC, Olson J, Louie A, et al. Role of macrophage sialoadhesin in host defense against the sialylated pathogen group B streptococcus. J Mol Med (Berl) 2014; 92:951-959.
30. Ali SR, Fong JJ, Carlin AF, et al. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B streptococcus. J Exp Med 2014; 211:1231-1242.
31. Patras KA, Rosler B, Thoman ML, et al. Characterization of host immunity during persistent vaginal colonization by group B streptococcus. Mucosal Immunol 2015; 8:1339-1348.
32. De Gregorio PR, Juarez Tomas MS, Nader-Macias ME. Immunomodulation of lactobacillus reuteri CRL1324 on group B streptococcus vaginal colonization in a murine experimental model. Am J Reprod Immunol 2016; 75: 23-35.
33. Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012:985646.
34. Edwards MS, Munoz FM, Baker CJ. Antibodies to type III group B streptococcal polysaccharide in breast milk. Pediatr Infect Dis J 2004; 23:961-963.
35. Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B streptococcus in infant infection. Pediatrics 1981; 68:544-549.
36. Feldman RG, Ferrante A. Prevalence of antigroup B streptococcal type III capsular IgG antibodies in the United Kingdom and an analysis of their specific IgG subclasses. J Infect Dis 1990; 162:883-887.
37. Lin FY, Philips JB 3rd, Azimi PH, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001; 184:1022-1028.
38. Lin FY, Weisman LE, Azimi PH, et al. Level of maternal IgG antigroup B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004; 190:928-934.
39. Matsubara K, Katayama K, Baba K, et al. Seroepidemiologic studies of serotype VIII group B streptococcus in Japan. J Infect Dis 2002; 186:855-858.
40. Carey V, Baker C, Platt R. Bayesian inference on protective antibody levels using case-control data. Biometrics 2001; 57:135-142.
41. Wilson CB. Immunologic basis for increased susceptibility of the neonate to infection. J Ped 1986; 108:1-12.
42. Kenzel S, Henneke P.The innate immune system and its relevance toneonatal sepsis. Curr Opin Infect Dis 2006; 19:264-270.
43. Epalza C, Goetghebuer T, Hainaut M, et al. High incidence of invasive group B streptococcal infections in HIV-exposed uninfected infants. Pediatrics 2010; 126:23.
44. Cutland CL, Schrag SJ, Thigpen MC, et al. Increased risk for group B streptococcus sepsis in young infants exposed to HIV, Soweto, South Africa, 2004-2008(1). Emerg Infect Dis 2015; 21:638-645.
45. Kwatra G, Adrian PV, Cutland CL, et al. Impact of cell mediated immune response to group B streptococcus on host clearance of colonization. Cape Town: International African Vaccine Conference; 2012.
46. Heath PT, Feldman RG. Vaccination against group B streptococcus. Expert Rev Vaccines 2005; 4:207-218.
47. Lachenauer CS, Baker CJ, Baron MJ, et al. Quantitative determination of immunoglobulin G specific for group B streptococcal beta C protein in human maternal serum. J Infect Dis 2002; 185:368-374.
48. Manning SD, Wood S, Kasha K, et al. Naturally occurring antibodies for the group B streptococcal surface immunogenic protein (Sip) in pregnant women and newborn babies. Vaccine 2006; 24:6905-6912.
49. Larsson C, Lindroth M, Nordin P, et al. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed 2006; 91:F403-F408.
50. Pannaraj PS, Kelly JK, Madoff LC, et al. Group B Streptococcus bacteremia elicits beta C protein-specific IgM and IgG in humans. J Infect Dis 2007; 195:353-356.
51. Pannaraj PS, Kelly JK, Rench MA, et al. Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease. Vaccine 2008; 26:502-508.
52. Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009; 199:108-115.
53. Santi I, Maione D, Galeotti CL, et al. BibA induces opsonizing antibodies conferring in vivo protection against group B streptococcus. J Infect Dis 2009; 200:564-570.
54. Meinke AL, Senn BM, Visram Z, et al. Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens. Vaccine 2010; 28:6997-7008.
55. Landwehr-Kenzel S, Henneke P. Interaction of streptococcus agalactiae and cellular innate immunity in colonization and disease. Front Immunol 2014; 5:519.
56. Goldman AS. The immune system of human milk: antimicrobial, antiinflam-matory and immunomodulating properties. Pediatr Infect Dis J 1993; 12:664-671.
57. Telemo E, Hanson LA. Antibodies in milk. J Mammary Gland Biol Neoplasia 1996; 1:243-249.
58. Le Doare K, Kampmann B. Breast milk and group B streptococcal infection: vector of transmission or vehicle for protection? Vaccine 2014; 32:3128-3132.